Please assess the completion status of the following clinical trial:

Trial Title: HL2351 CAPS Phase II Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented molecular diagnosis of NALP3 mutation or diagnosis of CAPS based on sign and symptom~* Diagnosis of CAPS based on signs and symptoms~* Current stable doses of anakinra, alone or in combination with methotrexate or corticosteroids~Exclusion Criteria:~* Patient been diagnosed with a hereditary periodic fever syndrome or autoinflammatory disease other than CAPS~* Patients whose disease is inadequately controlled on current stable doses of anakinra, alone or in combination with methotrexate or corticosteroids

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- HL2351 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).